BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Alessio A, Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Rev Anticancer Ther 2021;21:927-39. [PMID: 34167423 DOI: 10.1080/14737140.2021.1948329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Psilopatis I, Damaskos C, Garmpi A, Sarantis P, Koustas E, Antoniou EA, Dimitroulis D, Kouraklis G, Karamouzis MV, Vrettou K, Marinos G, Kontzoglou K, Garmpis N. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? Int J Mol Sci 2023;24. [PMID: 36769004 DOI: 10.3390/ijms24032685] [Reference Citation Analysis]
2 Chen J, Lu L, Qu C, A G, Deng F, Cai M, Chen W, Zheng L, Chen J. Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy. Front Med 2022;9. [DOI: 10.3389/fmed.2022.981001] [Reference Citation Analysis]
3 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
4 Ishikawa N, Kamimura K, Endo S, Ishii S, Ogawa K, Sakai N, Abe H, Ko M, Shibata O, Koseki Y, Yokoyama J, Sakamaki A, Terai S. Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature. Intern Med . [DOI: 10.2169/internalmedicine.9341-22] [Reference Citation Analysis]